Navigation Links
Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
Date:2/22/2010

LOS ANGELES, Feb. 22 /PRNewswire/ -- Ritter Pharmaceuticals (www.ritterpharmaceuticals.com), a company dedicated to helping individuals live a healthier and happier life style through improved digestion, announced today that it will join the leading lactose intolerance experts around the country at the NIH Consensus Development Conference for Lactose Intolerance and Health in Bethesda, Maryland from February 22-24. The event will discuss topics regarding lactose intolerance and will be focused on answering questions such as the prevalence of lactose intolerance and health outcomes of diets which exclude dairy products.

Today, a significant concern among individuals, including healthcare providers, is that avoidance of dairy products leads to insufficient intake of calcium, vitamin D, and other nutrients. These deficiencies may cause weaker bone health, increased risk of bone fractures, osteoporosis and more serious issues such as hypertension, breast cancer, and colon cancer. Despite the risks associated with a dairy exclusion diet, 70% of the time physicians still recommend dairy avoidance to manage symptoms of lactose intolerance.(1)

"Making sure people eat adequate amounts of dairy is essential, but many lactose intolerant individuals do not choose to do so because of painful or uncomfortable symptoms," said Dennis Savaiano, Ph.D., Dean of the College of Consumer and Family Sciences, Foods and Nutrition at Purdue University and speaker at the upcoming NIH conference.

"Lactagen®, a product unlike any other on the market, is a dietary supplement program taken over 38 days, developed to help reduce symptoms of lactose intolerance," said Andrew Ritter, President and CEO of Ritter Pharmaceuticals, the makers of Lactagen®.  "Clinical data as well as our customers surveyed have shown that Lactagen® is nearly 80% effective at significantly reducing lactose intolerance symptoms."

Lactase supplements often prove to be ineffective or unreliable as reported in a recent study showing that only 26% of lactose intolerant individuals were satisfied with taking lactase supplements.(1)

About Ritter Pharmaceuticals

Ritter Pharmaceuticals is dedicated to helping individuals live a healthier and happier life style through improved digestion.  Ritter Pharmaceuticals focuses on the discovery, development and commercialization of innovative therapeutic treatments for gastrointestinal diseases and conditions.  One of these products is Lactagen®, a dietary supplement developed to help reduce symptoms of lactose intolerance.

(1) "Physicians' and Payors' Perception and Intended Use to Treat Lactose Intolerance." Study performed by Engage Health, June, 2008.

SOURCE Ritter Pharmaceuticals

Back to top

RELATED LINKS
http://www.ritterpharmaceuticals.com/
http://www.lactagen.com

'/>"/>

SOURCE Ritter Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
2. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
3. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
4. Transdel Pharmaceuticals Announces Management Reorganization
5. Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide
6. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
7. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
8. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
9. Endo Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 22, 2010
10. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
11. ISTA Pharmaceuticals Announces 2010 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):